BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial

Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...

September 04, 2026 | News

Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

September 04, 2026 | News

ASTRI, Saint Francis University Partner to Advance AI-Enabled Biomaterials and Digital Health

The Hong Kong Applied Science and Technology Research Institute (ASTRI) and Saint Francis University (SFU) have signed a Memorandum of Understanding (MoU) ...

August 26, 2026 | News

GenScript CEO Sherry Shao Sees AI-Enabled Drug Discovery as Key Growth Engine After Strong H1 2026

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue GenScript Biotech Corporation (HKEX: 154...

August 20, 2026 | Company results

Insilico Nominates AI-Designed ISM0900 as Preclinical Candidate for Cardiovascular Risk

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced the nom...

August 14, 2026 | News

Ommo Technologies Raises Series A to Scale Spatial Intelligence Platform for Physical AI

VMS Group, a global alternative investment specialist, announced that its portfolio company, Ommo Technologies (Ommo), a spatial intelligence tec...

August 13, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...

August 11, 2026 | News

Pathos AI Secures Up to $2.2 Billion Global Licensing Deal for Alphamab's First-in-Class Bispecific ADC

Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Al...

August 06, 2026 | News

Ascletis Initiates Global Phase III Trial for Oral GLP-1 Obesity Drug ASC30

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight acr...

August 05, 2026 | News

Insilico Medicine's AI-Designed Cancer Drug Secures FDA Fast Track Status

FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the...

July 31, 2026 | News

Menarini Asia-Pacific, Pharmacosmos Partner to Expand Cosela® Access Across APAC

Menarini Asia-Pacific announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) acr...

July 23, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced NSCLC

Akeso, Inc. (9926.HK) (announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2...

July 21, 2026 | News

Hong Kong Makes Its Case as Asia’s Biotech Super-Connector: Capital, Regulation and Scale Converge

Hong Kong is seeking to redefine its place in the global life sciences economy. No longer content to be viewed primarily as a financial gateway int...

July 20, 2026 | News

Takeda Partners with Insilico Medicine in Up to $600M AI Drug Discovery Collaboration

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas Insilico Medicine ("Insilico" HKEX:3696),...

July 03, 2026 | News

Stay Connected